accountGlaxoSmithKline plans to cut costs in its struggling European drugs division and promised investors a return to growth this year, after failing to deliver a hoped-for sales and margin recovery in 2012.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Glaxo Promises Growth After 2012 Shortfall
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account